STOCK TITAN

Tiziana Life Sciences Ltd Com - TLSA STOCK NEWS

Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a progressive clinical-stage biotechnology company committed to developing transformative therapies targeting neurodegenerative and lung diseases. The company leverages innovative drug-delivery technologies to create novel treatments aimed at improving patient outcomes.

Key to Tiziana's portfolio are two prominent compounds: Milciclib and Foralumab. Milciclib, an inhibitor of cyclin-dependent kinases, is in Phase II clinical trials for thymic carcinoma, aiming to provide new hope for patients who have exhausted chemotherapy options. Foralumab, noted for being the only fully human-engineered anti-CD3 monoclonal antibody, is in various stages of clinical development for multiple sclerosis, autoimmune, and inflammatory diseases.

In a significant advancement, Tiziana recently reported positive clinical outcomes from its Expanded Access Program (EAP) for non-active secondary progressive multiple sclerosis (na-SPMS). Intranasal administration of Foralumab led to remarkable improvement in fatigue symptoms in 70% of patients over six months, as measured by the Modified Fatigue Impact Scale (MFIS). These results signify a groundbreaking step in addressing an unmet need in MS treatment.

The company's commitment to innovation is backed by strategic partnerships with prestigious institutions like Harvard Medical School and Brigham and Women's Hospital. Tiziana’s leadership team brings extensive experience in drug development and commercialization, ensuring a firm trajectory toward regulatory approvals and market entry.

Moreover, Tiziana’s pipeline includes potential therapies for conditions like ALS, Alzheimer's, and Crohn's Disease, underscoring its dedication to tackling a broad spectrum of debilitating conditions. The company’s forward-looking approach aims to revolutionize treatment paradigms through enhanced drug delivery systems that promise increased efficacy and reduced side effects.

With a robust clinical pipeline, strategic collaborations, and innovative technologies, Tiziana Life Sciences Ltd. remains at the forefront of biopharmaceutical research, poised to make significant strides in the field of immunomodulation therapies.

Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA) has secured $3.4 million in non-dilutive funding. This funding will support their ongoing Phase 2 trial for intranasal foralumab in treating non-active secondary progressive multiple sclerosis (na-SPMS) and advancements in Alzheimer's Disease research. Chairman and acting CEO, Gabriele Cerrone, emphasized the importance of this funding in propelling their research and expressed their intention to seek further non-dilutive funding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
none
-
Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA) announced that the FDA has granted approval for the use of intranasal foralumab in treating a patient with moderate Alzheimer's disease under an Expanded Access IND. This pathway allows patients with serious conditions, lacking other therapy options, to access investigational drugs. Dr. Howard L. Weiner, Principal Investigator and Chairman of Tiziana’s Scientific Advisory Board, expressed optimism about the potential of nasal foralumab to slow cognitive decline, citing its effectiveness in reducing microglial inflammation in progressive MS patients. The company plans to closely monitor treatment responses while preparing for a Phase 2 study targeting early symptomatic Alzheimer’s disease. Gabriele Cerrone, Chairman and acting CEO, emphasized the groundbreaking potential of foralumab in addressing neuroinflammation caused by toxic protein accumulation in the brain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.12%
Tags
none
-
Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA) announced that the FDA has accepted its submission for Fast Track Designation for its intranasal foralumab treatment for non-active, secondary-progressive multiple sclerosis (na-SPMS). Foralumab is a fully human anti-CD3 monoclonal antibody designed to induce T regulatory cells. In an Intermediate-Sized Patient Population Expanded Access program, 70% of the ten dosed patients demonstrated a clinically meaningful reduction in fatigue, with disease stability observed over six months. The Fast Track submission included data from both animal models and clinical experience. If granted, this designation could expedite FDA review processes, which is significant given the lack of approved therapies for na-SPMS. Chairman and acting CEO Gabriele Cerrone highlighted the potential of Fast Track Designation to enhance development through increased FDA interaction and partnership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
Rhea-AI Summary

Tiziana Life Sciences (NASDAQ: TLSA) reported a 80% qualitative improvement in PET imaging for non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients receiving intranasal foralumab for at least six months. The FDA has permitted the enrollment of an additional 20 patients in the Expanded Access Program (EA), aiming to gather more data and analyze for further insights. The company also applied for FDA Orphan Drug Designation for foralumab to treat na-SPMS. This development is a significant milestone for Tiziana's immunomodulation therapies, as stated by Gabriele Cerrone, the acting CEO and founder.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none
-
Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA), a biotechnology company, has applied for a grant from the ALS Association to fund a clinical trial for intranasal foralumab, an anti-CD3 monoclonal antibody. The grant is part of the Hoffman ALS Clinical Trial Awards Program. The trial aims to evaluate the safety, dosing, and biomarkers of foralumab in ALS patients using cutting-edge imaging techniques like PET scans. Previously, foralumab showed promising results in an Expanded Access Program for non-active secondary progressive multiple sclerosis. The company hopes the grant will support a 6-month trial involving 20 participants, advancing their efforts to develop effective ALS treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Tiziana Life Sciences announced that Dr. Howard L. Weiner, its Scientific Advisory Board Chairman, will receive the 'Giants of MS' award for his contributions to multiple sclerosis (MS) research.

The award will be presented at the Consortium of Multiple Sclerosis Centers annual meeting on May 30, 2024.

Dr. Weiner is celebrated for his work on innovative treatments like intranasal foralumab, which shows promise in improving the lives of MS patients.

Foralumab has shown positive results in an Expanded Access Program, with 70% of patients experiencing improved fatigue.

The drug is also undergoing a Phase 2a trial, with data expected in 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Tiziana Life Sciences, a biotechnology company, files for Orphan Drug Designation for intranasal foralumab for treating non-active secondary progressive Multiple Sclerosis, aiming to be the first therapy to receive this designation. Supported by clinical evidence, the drug has shown positive results in an Expanded Access Program, improving fatigue in 70% of patients. A Phase 2a trial is ongoing, with a data readout expected in 2025. Orphan Drug Designation brings significant benefits if approved.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
-
Rhea-AI Summary
Tiziana Life Sciences reports positive 3-month neuroimaging scores in multiple sclerosis patients receiving intranasal foralumab. The company announced quantitative data showing improvement in White Matter Z-scores in patients with non-active secondary progressive multiple sclerosis. Dr. Tarun Singhal presented data demonstrating a reduction in microglial activation, indicating a positive effect on brain inflammation. A peer-reviewed journal has published the research findings. Tiziana is currently conducting a double-blind, placebo-controlled study to further evaluate intranasal foralumab's impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.33%
Tags
none
-
Rhea-AI Summary
Tiziana Life Sciences announces FDA allowance for additional patients in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program, with positive clinical data showing improvements in patients' conditions without serious side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
none
Rhea-AI Summary
Tiziana Life Sciences announced additional positive clinical results from its Expanded Access Program for non-active secondary progressive multiple sclerosis patients, with 70% showing improvement in fatigue after six months of follow-up. All patients stabilized or improved on nasal foralumab treatment. The findings highlight the potential of Tiziana's therapy to address the critical unmet need for individuals living with MS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.94%
Tags
none

FAQ

What is the current stock price of Tiziana Life Sciences Com (TLSA)?

The current stock price of Tiziana Life Sciences Com (TLSA) is $1.29 as of February 28, 2025.

What is the market cap of Tiziana Life Sciences Com (TLSA)?

The market cap of Tiziana Life Sciences Com (TLSA) is approximately 117.3M.

What is Tiziana Life Sciences Ltd. specialized in?

Tiziana Life Sciences Ltd. specializes in developing transformative therapies for neurodegenerative and lung diseases using innovative drug-delivery technologies.

What are the key compounds in Tiziana's pipeline?

The key compounds in Tiziana's pipeline are Milciclib, an inhibitor of cyclin-dependent kinases, and Foralumab, the only fully human-engineered anti-CD3 monoclonal antibody.

What recent clinical results has Tiziana announced?

Tiziana announced positive results from its Expanded Access Program for non-active secondary progressive multiple sclerosis (na-SPMS), where 70% of patients showed improvement in fatigue symptoms after six months of treatment with intranasal Foralumab.

Who are Tiziana Life Sciences' key partners?

Tiziana partners with prestigious institutions like Harvard Medical School and Brigham and Women's Hospital to advance its clinical research and development.

What diseases are targeted by Foralumab?

Foralumab targets multiple sclerosis, autoimmune diseases like ulcerative colitis, and inflammatory diseases such as Crohn's Disease and type-1 diabetes.

What is unique about Tiziana’s drug delivery approach?

Tiziana uses a nasal delivery method for Foralumab, which has demonstrated enhanced efficacy, safety, and tolerability compared to traditional intravenous delivery.

What is the status of Milciclib's clinical development?

Milciclib is currently in Phase II clinical trials for thymic carcinoma, aiming to provide a new treatment option for patients who have previously undergone chemotherapy.

Who leads Tiziana Life Sciences?

Tiziana is led by a team of experienced executives, including Chairman and acting CEO Gabriele Cerrone, who have extensive backgrounds in drug development and commercialization.

What is the significance of Tiziana's Expanded Access Program?

The Expanded Access Program allows patients with non-active secondary progressive multiple sclerosis (na-SPMS) to receive treatment with Foralumab, showing significant improvements in fatigue and stability in disease progression.

How does Tiziana Life Sciences contribute to biopharmaceutical research?

Tiziana is at the forefront of biopharmaceutical research, developing new therapies and drug delivery systems to address unmet needs in neurodegenerative and autoimmune diseases.
Tiziana Life Sciences Ltd Com

Nasdaq:TLSA

TLSA Rankings

TLSA Stock Data

117.32M
71.30M
35.56%
1.78%
0.52%
Biotechnology
Healthcare
Link
United Kingdom
London